Extended Data Fig. 1: Kaplan-Meier Curves for PFS by BICR Assessment (Interim Analysis). | Nature Medicine

Extended Data Fig. 1: Kaplan-Meier Curves for PFS by BICR Assessment (Interim Analysis).

From: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Extended Data Fig. 1: Kaplan-Meier Curves for PFS by BICR Assessment (Interim Analysis).

Data cutoff: June 21, 2023; the protocol-specified interim analysis of PFS. The 95% CI of median PFS was determined using the Brookmeyer and Crowley method with log-log transformation. HR along with 95% CI was estimated by a stratified Cox proportional hazards model. The P value was calculated by a stratified log-rank test. The multiplicity-adjusted, one-sided alpha at this interim analysis (determined using the Lan-DeMets O’Brien-Fleming spending function) was 0.0104. The exact one-sided P value was 2.0 × 10−11. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; sac-TMT, sacituzumab tirumotecan.

Back to article page